Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: STAT1

Gene summary for STAT1

Gene summary.

Gene information	Species	Human
	Gene symbol	STAT1
	Gene ID	6772
	Gene name	signal transducer and activator of transcription 1
	Gene Alias	CANDF7
	Cytomap	2q32.2
	Gene Type	protein-coding
	GO ID	GO:0000122
	UniProtAcc	P42224

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6772	STAT1	GSM4909281	Human	Breast	IDC	7.56e-46	8.44e-01	0.21
6772	STAT1	GSM4909287	Human	Breast	IDC	3.77e-26	7.86e-01	0.2057
6772	STAT1	GSM4909290	Human	Breast	IDC	8.59e-18	6.21e-01	0.2096
6772	STAT1	GSM4909293	Human	Breast	IDC	8.12e-28	5.55e-01	0.1581
6772	STAT1	GSM4909304	Human	Breast	IDC	3.64e-06	3.30e-01	0.1636
6772	STAT1	GSM4909307	Human	Breast	IDC	2.18e-22	5.87e-01	0.1569
6772	STAT1	GSM4909308	Human	Breast	IDC	1.04e-28	6.88e-01	0.158
6772	STAT1	GSM4909309	Human	Breast	IDC	2.37e-04	3.99e-01	0.0483
6772	STAT1	GSM4909317	Human	Breast	IDC	5.48e-09	4.44e-01	0.1355
6772	STAT1	GSM4909319	Human	Breast	IDC	2.30e-05	-9.00e-02	0.1563
6772	STAT1	GSM4909321	Human	Breast	IDC	1.48e-03	2.38e-01	0.1559
6772	STAT1	M1	Human	Breast	IDC	7.08e-04	3.22e-01	0.1577
6772	STAT1	M2	Human	Breast	IDC	3.44e-04	5.62e-01	0.21
6772	STAT1	NCCBC5	Human	Breast	DCIS	7.42e-10	5.10e-01	0.2046
6772	STAT1	P1	Human	Breast	IDC	9.28e-10	4.41e-01	0.1527
6772	STAT1	P2	Human	Breast	IDC	1.05e-32	1.09e+00	0.21
6772	STAT1	P3	Human	Breast	IDC	5.16e-04	6.08e-01	0.1542
6772	STAT1	DCIS2	Human	Breast	DCIS	6.12e-28	1.81e-01	0.0085
6772	STAT1	CA_HPV_1	Human	Cervix	CC	4.59e-47	9.77e-01	0.0264
6772	STAT1	CA_HPV_2	Human	Cervix	CC	2.00e-02	3.85e-01	0.0391

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000697914	Breast	IDC	response to oxidative stress	83/1434	446/18723	2.36e-14	7.06e-12	83
GO:001603214	Breast	IDC	viral process	75/1434	415/18723	1.98e-12	4.02e-10	75
GO:000030214	Breast	IDC	response to reactive oxygen species	46/1434	222/18723	4.12e-10	4.59e-08	46
GO:005079214	Breast	IDC	regulation of viral process	36/1434	164/18723	6.55e-09	5.03e-07	36
GO:004254213	Breast	IDC	response to hydrogen peroxide	32/1434	146/18723	4.65e-08	3.02e-06	32
GO:003410114	Breast	IDC	erythrocyte homeostasis	27/1434	129/18723	1.34e-06	5.75e-05	27
GO:000226214	Breast	IDC	myeloid cell homeostasis	30/1434	157/18723	2.64e-06	1.01e-04	30
GO:005067313	Breast	IDC	epithelial cell proliferation	60/1434	437/18723	7.13e-06	2.15e-04	60
GO:003009914	Breast	IDC	myeloid cell differentiation	54/1434	381/18723	8.07e-06	2.39e-04	54
GO:005067812	Breast	IDC	regulation of epithelial cell proliferation	54/1434	381/18723	8.07e-06	2.39e-04	54
GO:000941013	Breast	IDC	response to xenobiotic stimulus	62/1434	462/18723	1.05e-05	2.88e-04	62
GO:005159114	Breast	IDC	response to cAMP	20/1434	93/18723	2.00e-05	4.91e-04	20
GO:003166714	Breast	IDC	response to nutrient levels	62/1434	474/18723	2.33e-05	5.57e-04	62
GO:000181911	Breast	IDC	positive regulation of cytokine production	61/1434	467/18723	2.81e-05	6.58e-04	61
GO:000961211	Breast	IDC	response to mechanical stimulus	34/1434	216/18723	4.59e-05	1.03e-03	34
GO:004668312	Breast	IDC	response to organophosphorus	24/1434	131/18723	5.22e-05	1.12e-03	24
GO:000758412	Breast	IDC	response to nutrient	29/1434	174/18723	5.69e-05	1.20e-03	29
GO:007135613	Breast	IDC	cellular response to tumor necrosis factor	35/1434	229/18723	6.64e-05	1.35e-03	35
GO:00434348	Breast	IDC	response to peptide hormone	54/1434	414/18723	8.25e-05	1.61e-03	54
GO:190370612	Breast	IDC	regulation of hemopoiesis	49/1434	367/18723	9.74e-05	1.86e-03	49

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0517124	Breast	IDC	Coronavirus disease - COVID-19	86/867	232/8465	1.50e-28	9.72e-27	7.27e-27	86
hsa0516922	Breast	IDC	Epstein-Barr virus infection	45/867	202/8465	3.16e-07	6.05e-06	4.52e-06	45
hsa0516723	Breast	IDC	Kaposi sarcoma-associated herpesvirus infection	38/867	194/8465	5.87e-05	5.96e-04	4.46e-04	38
hsa0491916	Breast	IDC	Thyroid hormone signaling pathway	23/867	121/8465	2.45e-03	1.69e-02	1.27e-02	23
hsa0514012	Breast	IDC	Leishmaniasis	16/867	77/8465	4.35e-03	2.57e-02	1.92e-02	16
hsa0517134	Breast	IDC	Coronavirus disease - COVID-19	86/867	232/8465	1.50e-28	9.72e-27	7.27e-27	86
hsa0516932	Breast	IDC	Epstein-Barr virus infection	45/867	202/8465	3.16e-07	6.05e-06	4.52e-06	45
hsa0516733	Breast	IDC	Kaposi sarcoma-associated herpesvirus infection	38/867	194/8465	5.87e-05	5.96e-04	4.46e-04	38
hsa0491917	Breast	IDC	Thyroid hormone signaling pathway	23/867	121/8465	2.45e-03	1.69e-02	1.27e-02	23
hsa0514013	Breast	IDC	Leishmaniasis	16/867	77/8465	4.35e-03	2.57e-02	1.92e-02	16
hsa0516941	Breast	DCIS	Epstein-Barr virus infection	46/846	202/8465	5.60e-08	1.13e-06	8.33e-07	46
hsa0516743	Breast	DCIS	Kaposi sarcoma-associated herpesvirus infection	38/846	194/8465	3.43e-05	3.69e-04	2.72e-04	38
hsa0491922	Breast	DCIS	Thyroid hormone signaling pathway	23/846	121/8465	1.78e-03	1.22e-02	9.00e-03	23
hsa0516951	Breast	DCIS	Epstein-Barr virus infection	46/846	202/8465	5.60e-08	1.13e-06	8.33e-07	46
hsa0516753	Breast	DCIS	Kaposi sarcoma-associated herpesvirus infection	38/846	194/8465	3.43e-05	3.69e-04	2.72e-04	38
hsa0491932	Breast	DCIS	Thyroid hormone signaling pathway	23/846	121/8465	1.78e-03	1.22e-02	9.00e-03	23
hsa0517120	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa0516720	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa0516920	Cervix	CC	Epstein-Barr virus infection	57/1267	202/8465	7.30e-07	7.39e-06	4.37e-06	57
hsa0514514	Cervix	CC	Toxoplasmosis	34/1267	112/8465	2.42e-05	1.82e-04	1.08e-04	34

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
STAT1	MES	Cervix	ADJ	TAP1,WARS,TAP2, etc.	6.27e-01
STAT1	STM	Cervix	ADJ	TAP1,WARS,TAP2, etc.	1.64e-01
STAT1	MDSC	Lung	Healthy	SLAMF8,IFIT3,GBP1, etc.	8.68e-01

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

STAT1

SNV

Missense_Mutation

novel

c.567N>C

p.Lys189Asn

p.K189N

P42224

protein_coding

tolerated(0.43)

benign(0.014)

TCGA-A7-A3IZ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

STAT1

SNV

Missense_Mutation

c.1778N>T

p.Asp593Val

p.D593V

P42224

protein_coding

deleterious(0.03)

benign(0.392)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

STAT1

SNV

Missense_Mutation

c.1236G>C

p.Gln412His

p.Q412H

P42224

protein_coding

deleterious(0)

probably_damaging(0.931)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

STAT1

insertion

Nonsense_Mutation

novel

c.65_66insAGGTT

p.Tyr22Ter

p.Y22*

P42224

protein_coding

TCGA-A8-A09W-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

STAT1

insertion

Frame_Shift_Ins

novel

c.63_64insATCCCCATTTTAAAGATGAGAAAAC

p.Tyr22IlefsTer10

p.Y22Ifs*10

P42224

protein_coding

TCGA-A8-A09W-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

STAT1

insertion

In_Frame_Ins

novel

c.46_47insGCCTGG

p.Leu15_Glu16insGlyLeu

p.L15_E16insGL

P42224

protein_coding

TCGA-BH-A0BG-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

STAT1

SNV

Missense_Mutation

novel

c.431G>T

p.Ser144Ile

p.S144I

P42224

protein_coding

tolerated(0.18)

benign(0.021)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

STAT1

SNV

Missense_Mutation

novel

c.227A>G

p.Asn76Ser

p.N76S

P42224

protein_coding

tolerated(0.13)

benign(0.023)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

STAT1

SNV

Missense_Mutation

c.1035N>C

p.Leu345Phe

p.L345F

P42224

protein_coding

deleterious(0.01)

possibly_damaging(0.629)

TCGA-C5-A1BI-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

STAT1

SNV

Missense_Mutation

c.1945N>T

p.Arg649Cys

p.R649C

P42224

protein_coding

deleterious(0.03)

possibly_damaging(0.48)

TCGA-C5-A1BQ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		AVT-02 UE
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		PMID26394986-Compound-10
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		Peptidomimetic analog 5
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		IPRIFLAVONE	IPRIFLAVONE
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		GARCINOL	GARCINOL
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		GUTTIFERONE K	GUTTIFERONE K
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		Peptide analog 8
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		Platinum IV complexe 1
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		Oxazole derivative 1
6772	STAT1	DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE		10-METHOXYLRUTAECARPINE	CHEMBL85826

Page: 1 2